Multiple myeloma is the most common hematologic malignancy to result in end-stage kidney disease. Due to frequent relapses and extensive renal involvement, it has historically been seen as a relative contraindication to kidney transplantation. As newer medications arrive and overall prognosis improves, the question of whether kidney transplantation is now appropriate has resurfaced. A review of the published literature suggests that it still carries substantial risk. In addition, current literature is of insufficient quality to advocate routine allocation of kidneys to this complex population.
SegevDLMuzaaleADCaffoBS, et al. Perioperative mortality and long-term survival following live kidney donation. JAMA2010; 303(10): 959–966.
2.
MuzaaleADMassieABWangMC, et al. Risk of end-stage renal disease following live kidney donation. JAMA2014; 311(6): 579–586.
3.
FonsecaRAbouzaidSBonafedeM, et al. Trends in overall survival and costs of multiple myeloma, 2000-2014. Leukemia2017; 31(9): 1915–1921.
4.
DecourtAGondouinBDelaroziereJC, et al. Trends in survival and renal recovery in patients with multiple myeloma or light-chain amyloidosis on chronic dialysis. Clin J Am Soc Nephrol2016; 11(3): 431–441.
5.
EvisonFSanghaJYadavP, et al. A population-based study of the impact of dialysis on mortality in multiple myeloma. Br J Haematol2018; 180(4): 588–591.
6.
JosephNSGentiliSKaufmanJL, et al. High-risk multiple myeloma: definition and management. Clin Lymphoma Myeloma Leuk2017; 17S: S80–S87.
7.
PennI. Evaluation of transplant candidates with pre-existing malignancies. Ann Transplant1997; 2(4): 14–17.
8.
LeungNLagerDJGertzMA, et al. Long-term outcome of renal transplantation in light-chain deposition disease. Am J Kidney Dis2004; 43(1): 147–153.
9.
IggoNPalmerABSevernA, et al. Chronic dialysis in patients with multiple myeloma and renal failure: a worthwhile treatment. Q J Med1989; 73(270): 903–910.
10.
van BommelEF. Multiple myeloma treatment in dialysis-dependent patients: to transplant or not to transplant?Nephrol Dial Transplant1996; 11(7): 1486–1487.
11.
KormannRPouteil-NobleCMullerC, et al. Kidney transplantation for active multiple myeloma or smoldering myeloma: a case–control study. Clin Kidney J2019; sfz128: 1–11.
12.
HartASmithJMSkeansMA, et al. OPTN/SRTR 2017 annual data report: kidney. Am J Transplant2019; 19(Suppl. 2): 19–123.
13.
HedvatJNairVMikoL, et al. Outcomes of renal transplantation in patients with previous hematologic malignancies. J Onco-Nephrol2019; 3(3): 124–130.
14.
LumELKogutNPhamT, et al. Kidney transplantation in patients with active multiple myeloma: case reports. Transplant Direct2017; 3(8): e200.
15.
LeTXWolfJLPeraltaCA, et al. Kidney transplantation for kidney failure due to multiple myeloma: case reports. Am J Kidney Dis2017; 69(6): 858–862.
16.
DominguezJIde AmestiMMajersonA. Hypothermic machine perfusion versus static cold preservation in kidney transplantation. Medwave2018; 18(7): e7360.
17.
ShahSIbrahimMDelaneyM, et al. Risk of relapse of multiple myeloma following kidney transplantation. Clin Kidney J2019; 12(2): 216–223.
18.
HuskeyJLHeilmanRLKhamashH, et al. Kidney transplant in the era of modern therapy for multiple myeloma. Transplantation2018; 102(12): 1994–2001.
19.
ChenYBEliasNHeherE, et al. Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure. Blood2019; 134(2): 211–215.
20.
SpitzerTRTolkoff-RubinNCosimiB, et al. Twenty year follow up of histocompatibility leukocyte antigen-matched kidney and bone marrow co-transplantation for multiple myeloma with end stage renal disease: lessons learned. Transplantation2019; 103(11): 2366–2372
21.
Fernandez-CaballeroMSalmeronDDolores ChirlaqueM, et al. Increasing therapy-related myeloid neoplasms in multiple myeloma. Eur J Clin Invest2019; 49(2): e13050.
22.
BhatiaS. Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up. Expert Rev Hematol2011; 4(4): 437–452; quiz 453–454.
23.
CuzickJErskineSEdelmanD, et al. A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council’s working party on leukaemia in adults. Br J Cancer1987; 55(5): 523–529.
24.
LumELHuangEBunnapradistS, et al. Acute kidney allograft rejection precipitated by lenalidomide treatment for multiple myeloma. Am J Kidney Dis2017; 69(5): 701–704.
25.
MeyersDEAdu-GyamfiBSeguraAM, et al. Fatal cardiac and renal allograft rejection with lenalidomide therapy for light-chain amyloidosis. Am J Transplant2013; 13(10): 2730–2733.
